May 9Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update
Jun 20, 2023Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Mar 30, 2023ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48Week Phase 2 Extension Study in PDD
Aug 9, 2022Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 Third Quarter Financial Results
Jul 31, 2022Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022
Mar 15, 2022Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from PDD study
Aug 12, 2021Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Result